Santarus moves up after Q2 beat, upbeat guidance

Shares of Santarus (SNTS) are trading higher by 8.6% premarket after the company handily beat estimates with Q2 results Tuesday evening.

Q2 Y/Y revenue growth by product: Glumetza, 39%; Zegerid, 109%; Cycloset, 115%; Fenoglide, flat.

The company is raising FY13 guidance based on the "robust" quarterly performance.

FY13 outlook: Adjusted EPS of $1.21-1.26 on revenue of $355-360M. Consensus is $0.85/ share on sales of $$345.81M. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs